Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly ...
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’ investigational ...
Morningstar4d
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
in a poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. Poster title: “Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination ...
Business Insider4d
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Highlights of the ASH poster presentation: TUS as Single Agent (n= 93 Patients) 60% and 42% CR/CRh with 80 mg TUS in FLT3 mutated and all-comer VEN-naïve AML 33% CRc & 42% ORR (CR, CRp ...
Financial Post4d
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
in a poster presentation at the 66 th American Society of Hematology (ASH) Annual Meeting in San Diego. Tuspetinib (TUS), being developed by Aptose and originally created by Hanmi Pharmaceutical Co., ...
Autolus Therapeutics presents clinical data updates at ASH meeting
Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations at the American Society of Hematology Annual ...
Stockhouse4d
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
in a poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. Poster title: “Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in ...
Taiho Oncology Data at ASH Annual Meeting Highlight Progress in Oral Therapies for Patients with Blood Cancers
Taiho Oncology, Inc., presented results of two studies focused on oral therapies for patients with myelodysplastic syndromes ...